Eli Lilly and Company (NYSE:LLY) Shares Purchased by Octavia Wealth Advisors LLC

Octavia Wealth Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 43.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 734 shares of the company’s stock after purchasing an additional 223 shares during the period. Octavia Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $428,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $27,000. Retirement Group LLC increased its holdings in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $33,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $35,000. Finally, Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $36,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Barclays raised their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Bank of America raised their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Citigroup raised their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Finally, Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $746.56 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm’s 50-day moving average price is $763.51 and its two-hundred day moving average price is $657.01. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The stock has a market capitalization of $709.35 billion, a P/E ratio of 128.72, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the company posted $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.